149 related articles for article (PubMed ID: 33323729)
1. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
Veenstra EB; de Groot DJA; Brouwers AH; Walenkamp AME; Noordzij W
Clin Nucl Med; 2021 Mar; 46(3):195-200. PubMed ID: 33323729
[TBL] [Abstract][Full Text] [Related]
2. Value of
Imperiale A; Boursier C; Sahakian N; Ouvrard E; Chevalier E; Sebag F; Addeo P; Taïeb D
J Nucl Med; 2022 Mar; 63(3):384-388. PubMed ID: 34272321
[TBL] [Abstract][Full Text] [Related]
3. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Ansquer C; Touchefeu Y; Faivre-Chauvet A; Leux C; Le Bras M; Régenet N; Fleury V; Maucherat B; Senellart H; Guyetant S; Carlier T; Scotet-Cérato E; Rauscher A; Frampas E; Kraeber-Bodéré F
Clin Nucl Med; 2021 Mar; 46(3):181-186. PubMed ID: 33315677
[TBL] [Abstract][Full Text] [Related]
5. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
Kroiss A; Putzer D; Frech A; Decristoforo C; Uprimny C; Gasser RW; Shulkin BL; Url C; Widmann G; Prommegger R; Sprinzl GM; Fraedrich G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
[TBL] [Abstract][Full Text] [Related]
6. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
[TBL] [Abstract][Full Text] [Related]
7. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
[TBL] [Abstract][Full Text] [Related]
9. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
Haug A; Auernhammer CJ; Wängler B; Tiling R; Schmidt G; Göke B; Bartenstein P; Pöpperl G
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):765-70. PubMed ID: 19137293
[TBL] [Abstract][Full Text] [Related]
10. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
12. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
[TBL] [Abstract][Full Text] [Related]
13. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
15.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
16. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
17.
Ouvrard E; Mestier L; Boursier C; Lachachi B; Sahakian N; Chevalier E; Mikail N; Carullo J; Bando-Delaunay A; Walter T; Malouf GG; Addeo P; Poncet G; Sebag F; Lebtahi R; Goichot B; Taïeb D; Imperiale A
J Nucl Med; 2022 Dec; 63(12):1865-1870. PubMed ID: 35589408
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]